BG Medicine Announces Availability of Galectin-3 Diagnostic Testing Through Atherotech Diagnostics Lab
Published: Jun 18, 2012
WALTHAM, Mass., June 18, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that Atherotech Diagnostics Lab (Atherotech) now offers galectin-3 testing services to its laboratory customers and physicians. To offer galectin-3 testing, Atherotech is using the BGM Galectin-3TM test, which was cleared by the U.S. Food and Drug Administration in November 2010, as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. Launch of galectin-3 testing by Atherotech represents further expansion of the availability of galectin-3 testing to practicing physicians in the United States.